Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review Sep 1, 2020 FDA grants Priority Review and sets PDUFA target action date of February 28, 2021
